Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 28, 2015 4:39 PM ET


Company Overview of Sagent Pharmaceuticals, Inc.

Company Overview

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis...

1901 North Roselle Road

Suite 700

Schaumburg, IL 60195

United States

Founded in 2006

466 Employees





Key Executives for Sagent Pharmaceuticals, Inc.

President, Chief Legal Officer and Corporate Secretary
Age: 50
Total Annual Compensation: $312.7K
Founder and Director
Age: 65
Total Annual Compensation: $615.2K
Chief Financial Officer and Executive Vice President
Age: 50
Total Annual Compensation: $330.8K
Executive Vice President of National Accounts & Corporate Development
Age: 71
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.

Sagent Pharmaceuticals, Inc. Key Developments

Sagent Pharmaceuticals, Inc. Appoints Michael Logerfo as President

Sagent Pharmaceuticals, Inc. announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President, effective April 15, 2015. In his new role as President, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the Chairman of the Board. Mr. Logerfo has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Sagent since March 2012.

Shlomo Yanai Joins Sagent Pharmaceuticals, Inc.'s Board of Directors

Sagent Pharmaceuticals, Inc. announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012.

Sagent Pharmaceuticals, Inc. Announces the Launch of Vancomycin Hydrochloride for Injection, USP

Sagent Pharmaceuticals, Inc. announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation. The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. According to IMS, for the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over 50% of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresS packaging and labeling, designed to help reduce medication errors.

Similar Private Companies By Industry

Company Name Region
CentraLabS Clinical Research, Inc. United States
Applied Therapeutics, Inc. United States
Noven Pharmaceuticals, Inc. United States
Chase Pharmaceuticals Corporation, Inc. United States
Napo Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

October 1, 2014
Omega Laboratories Limited

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sagent Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at